Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9524)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Nov 26, 2020 (publication date) through Dec 1, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Cardiology
ISSN
1949-8462
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Nso N, Antwi-Amoabeng D, Beutler BD, Ulanja MB, Ghuman J, Hanfy A, Nimo-Boampong J, Atanga S, Doshi R, Enoru S, Gullapalli N. Cardiac adverse events of immune checkpoint inhibitors in oncology patients: A systematic review and meta-analysis. World J Cardiol 2020; 12(11): 584-598 [PMID: 33312443 DOI: 10.4330/wjc.v12.i11.584] |
|---|---|
| URL: | https://www.wjgnet.com/1949-8462/full/v12/i11/584.htm |
| Number | Citing Articles |
| 1 |
Ja-Young Han, Young-Eun Seo, Jae-Hee Kwon, Jae Hyun Kim, Myeong Gyu Kim. Cardioprotective Effects of PARP Inhibitors: A Re-Analysis of a Meta-Analysis and a Real-Word Data Analysis Using the FAERS Database. Journal of Clinical Medicine 2024; 13(5): 1218 doi: 10.3390/jcm13051218
|
| 2 |
Dorte Lisbet Nielsen, Carsten Bogh Juhl, Ole Haagen Nielsen, Inna Markovna Chen, Joerg Herrmann. Immune Checkpoint Inhibitor–Induced Cardiotoxicity. JAMA Oncology 2024; 10(10): 1390 doi: 10.1001/jamaoncol.2024.3065
|
| 3 |
Giuseppe Panuccio, Pierpaolo Correale, Maria d’Apolito, Luciano Mutti, Rocco Giannicola, Luigi Pirtoli, Antonio Giordano, Demetrio Labate, Sebastiano Macheda, Nicole Carabetta, Youssef S. Abdelwahed, Ulf Landmesser, Pierfrancesco Tassone, Pierosandro Tagliaferri, Salvatore De Rosa, Daniele Torella. Immuno-related cardio-vascular adverse events associated with immuno-oncological treatments: an under-estimated threat for cancer patients. Basic Research in Cardiology 2024; doi: 10.1007/s00395-024-01077-7
|
| 4 |
Yiran Rong, John P. Bentley, Kaustuv Bhattacharya, Yi Yang, Yunhee Chang, Sally Earl, Sujith Ramachandran. Incidence and risk factors of immune‐related adverse events induced by immune checkpoint inhibitors among older adults with non‐small cell lung cancer. Cancer Medicine 2024; 13(1) doi: 10.1002/cam4.6879
|
| 5 |
Chun-Ka Wong, Tsun-Ho Lam, Song-Yan Liao, Yee-Man Lau, Hung-Fat Tse, Benjamin Y. F. So. Immunopathogenesis of Immune Checkpoint Inhibitor Induced Myocarditis: Insights from Experimental Models and Treatment Implications. Biomedicines 2023; 11(1): 107 doi: 10.3390/biomedicines11010107
|
| 6 |
Samuel Peter Heilbroner, Reed Few, Tomas G Neilan, Judith Mueller, Jitesh Chalwa, Francois Charest, Somasekhar Suryadevara, Christine Kratt, Andres Gomez-Caminero, Brian Dreyfus. Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach. Journal for ImmunoTherapy of Cancer 2021; 9(10): e002545 doi: 10.1136/jitc-2021-002545
|
| 7 |
Chin-Chin Ho, Shang-Liang Wu, Han-Yi Tsai, Yu-Wen Hu, Yuh-Lih Chang. A retrospective cohort study on the cardiotoxicity incidence rates of immune checkpoint inhibitors for oncology patients. Journal of the Chinese Medical Association 2023; 86(5): 499 doi: 10.1097/JCMA.0000000000000910
|
| 8 |
Danielle Delombaerde, Johan De Sutter, Lieselot Croes, Delphine Vervloet, Veronique Moerman, Nico Van de Veire, Anne-Marie Willems, Kristien Wouters, Marc Peeters, Hans Prenen, Christof Vulsteke. Extensive CArdioVAscular Characterization and Follow-Up of Patients Receiving Immune Checkpoint Inhibitors: A Prospective Multicenter Study. Pharmaceuticals 2023; 16(4): 625 doi: 10.3390/ph16040625
|
| 9 |
Umut Selamet, Rebecca S. Ahdoot, Reed Salasnek, Lama Abdelnour, Ramy M. Hanna. Onconephrology: mitigation of renal injury in chemotherapy administration. Current Opinion in Nephrology & Hypertension 2024; 33(2): 257 doi: 10.1097/MNH.0000000000000960
|
| 10 |
Mandana Chitsazan, Ahmad Amin, Luisa Ladel, Alyza Baig, Mitra Chitsazan. Cardiovascular Toxicity Associated With Immune Checkpoint Inhibitor Therapy: A Comprehensive Review. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 2023; 22(3): 69 doi: 10.1097/HPC.0000000000000327
|
| 11 |
Sarah E. Mudra, Danny L. Rayes, Ankit Agrawal, Ashwin K. Kumar, Jason Z. Li, Meredith Njus, Kevin McGowan, Kazi A. Kalam, Charalompos Charalampous, Mary Schleicher, Muhammad Majid, Alvena Syed, Abdullah Yesilyaprak, Allan L. Klein. Immune checkpoint inhibitors and pericardial disease: a systematic review. Cardio-Oncology 2024; 10(1) doi: 10.1186/s40959-024-00234-0
|
| 12 |
Tzu-Fei Wang, Alok A. Khorana, Marc Carrier. Thrombotic Complications Associated with Immune Checkpoint Inhibitors. Cancers 2021; 13(18): 4606 doi: 10.3390/cancers13184606
|
| 13 |
Chiara Pozzessere, Bianca Mazini, Patrick Omoumi, Mario Jreige, Leslie Noirez, Antonia Digklia, François Fasquelle, Christine Sempoux, Clarisse Dromain. Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors and CAR-T Cell Therapy: A Comprehensive Imaging-Based Review. Cancers 2024; 16(14): 2585 doi: 10.3390/cancers16142585
|
| 14 |
Virginia S. Hahn, Kathleen W. Zhang, Lova Sun, Vivek Narayan, Daniel J. Lenihan, Bonnie Ky. Heart Failure With Targeted Cancer Therapies. Circulation Research 2021; 128(10): 1576 doi: 10.1161/CIRCRESAHA.121.318223
|
| 15 |
Omoruyi Credit Irabor, Nicolas Nelson, Yash Shah, Muneeb Khan Niazi, Spencer Poiset, Eugene Storozynsky, Dinender K. Singla, Douglas Craig Hooper, Bo Lu. Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.940127
|
| 16 |
Jing Wu, Tingting Ni, Rong Deng, Yan Li, Qin Zhong, Fei Tang, Qi Zhang, Chunju Fang, Yingbo Xue, Yan Zha, Yu Zhang. Safety and efficacy of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: A systematic review and meta-analysis. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1065510
|
| 17 |
Masayoshi Oikawa, Takafumi Ishida, Yasuchika Takeishi. Cancer therapeutics-related cardiovascular dysfunction: Basic mechanisms and clinical manifestation. Journal of Cardiology 2023; 81(3): 253 doi: 10.1016/j.jjcc.2022.04.006
|
| 18 |
Walid Shalata, Rachel Steckbeck, Amjad Abu Salman, Omar Abu Saleh, Ashraf Abu Jama, Zoé Gabrielle Attal, Sondos Shalata, Hilmi Alnsasra, Alexander Yakobson. Perimyocarditis Associated with Immune Checkpoint Inhibitors: A Case Report and Review of the Literature. Medicina 2024; 60(2): 224 doi: 10.3390/medicina60020224
|
| 19 |
Liga Vidusa, Oskars Kalejs, Aija Maca-Kaleja, Ilze Strumfa. Role of Endomyocardial Biopsy in Diagnostics of Myocarditis. Diagnostics 2022; 12(9): 2104 doi: 10.3390/diagnostics12092104
|
| 20 |
Alessandro Inno, Andrea Chiampan, Laura Lanzoni, Matteo Verzè, Giulio Molon, Stefania Gori. Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer Patients. Frontiers in Cardiovascular Medicine 2021; 8 doi: 10.3389/fcvm.2021.652186
|
| 21 |
Feifei Wang, Qi Wei, Xinan Wu. Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.986357
|
| 22 |
Bingxun Li, Mingjie Lin, Lin Wu. Drug-induced AF: Arrhythmogenic Mechanisms and Management Strategies. Arrhythmia & Electrophysiology Review 2024; 13 doi: 10.15420/aer.2023.24
|
| 23 |
Honglin Li, Deting Han, Lei Zhang, Xiaoteng Feng, Huijie Li, Feiran Yang, Lucheng Song, Xiurong Li. Pd-1/L1 Inhibitors May Increase the Risk of Pericardial Disease in Non-Small-Cell Lung Cancer Patients: A Meta-Analysis and Systematic Review. Immunotherapy 2022; 14(7): 577 doi: 10.2217/imt-2021-0223
|
| 24 |
Diana Larisa Mocan-Hognogi, Sebastian Trancǎ, Anca Daniela Farcaş, Radu Florin Mocan-Hognogi, Andrada Viorica Pârvu, Anca Simona Bojan. Immune Checkpoint Inhibitors and the Heart. Frontiers in Cardiovascular Medicine 2021; 8 doi: 10.3389/fcvm.2021.726426
|
| 25 |
Zhuo Ma, Ximu Sun, Yi Zhang, Hao Li, Dan Sun, Zhuoling An, Yuhui Zhang. Risk of Thromboembolic Events in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-analysis of Randomized Controlled Trials. Thrombosis and Haemostasis 2022; 122(10): 1757 doi: 10.1055/s-0042-1749185
|
| 26 |
Jiayi Chen, Shuang Liu, Zheng Ruan, Kankan Wang, Xiaodong Xi, Jianhua Mao. Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk. Blood Reviews 2024; 67: 101220 doi: 10.1016/j.blre.2024.101220
|
| 27 |
Giselle Alexandra Suero-Abreu, Markella V. Zanni, Tomas G. Neilan. Atherosclerosis With Immune Checkpoint Inhibitor Therapy. JACC: CardioOncology 2022; 4(5): 598 doi: 10.1016/j.jaccao.2022.11.011
|
| 28 |
Younan Samuel, Aswin Babu, Foteini Karagkouni, Ayden Ismail, Sunyoung Choi, Stergios Boussios. Cardiac Toxicities in Oncology: Elucidating the Dark Box in the Era of Precision Medicine. Current Issues in Molecular Biology 2023; 45(10): 8337 doi: 10.3390/cimb45100526
|
| 29 |
Michał Gawlik, Jakub Michal Zimodro, Aleksandra Gąsecka, Krzysztof J. Filipiak, Sebastian Szmit. Cardiac Arrhythmias in Oncological Patients—Epidemiology, Risk Factors, and Management within the Context of the New ESC 2022 Guidelines. Current Oncology Reports 2023; 25(10): 1107 doi: 10.1007/s11912-023-01445-x
|
| 30 |
Lorenzo Braghieri, Ahmad Gharaibeh, Lubika Nkashama, Abdelrahman Abushouk, Osama Abushawer, Amir Mehdizadeh‐Shrifi, Bianca Honnekeri, Cassandra Calabrese, Venu Menon, Pauline Funchain, Patrick Collier, Diego Sadler, Rohit Moudgil. Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis. ESC Heart Failure 2024; doi: 10.1002/ehf2.15131
|